Phase 3 Investigation of Ampreloxetine Produces Positive Results for Neurogenic Orthostatic Hypotension

Theravance Biopharma Inc. has just released results from their 2nd Phase 3 investigation of Ampreloxetine as a therapy for symptomatic neurogenic orthostatic hypotension (nOH). Symptomatic nOH NOH is a rare…

Continue Reading Phase 3 Investigation of Ampreloxetine Produces Positive Results for Neurogenic Orthostatic Hypotension
New Survey Highlights the Prevalence of Neurogenic Orthostatic Hypotension in Parkinson’s Patients
andibreit / Pixabay

New Survey Highlights the Prevalence of Neurogenic Orthostatic Hypotension in Parkinson’s Patients

According to a story from Business Wire, a recent survey has revealed new findings about the frequency of neurogenic orthostatic hypotension (nOH) among Parkinson's disease patients. Around one in five…

Continue Reading New Survey Highlights the Prevalence of Neurogenic Orthostatic Hypotension in Parkinson’s Patients

TOMORROW Watch the Multiple System Atrophy Coalition Patient & Family Conference LIVE on Facebook

Have Neurogenic Orthostatic Hypotension or other MSA? Join the LIVE FEED and Watch the annual MSA Patient & Family Conference on Facebook On October 13-14, the Multiple System Atrophy (MSA)…

Continue Reading TOMORROW Watch the Multiple System Atrophy Coalition Patient & Family Conference LIVE on Facebook